US 9,265,598 B2Granted

Local vascular delivery of sirolimus to prevent restenosis following vascular injury

AssigneesCordis Corporation, Wyeth

InventorsRobert Falotico, Pallassana Narayanan

Life of this patent

Estimating the term…

Loading patent…

Abstract

Medical devices, and in particular implantable medical devices, may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Claims6

Dependent claims

A drug delivery device comprising:

an implantable intraluminal medical device;
a basecoat affixed to at least a portion of the implantable intraluminal medical device, the basecoat comprising a fluoropolymer poly(vinylidinefluoride/hexafluoropropylene) (PVDF/HFP) in a ratio of 60 percent by weight of PVDF to 40 percent by weight of HFP;
at least one anti-inflammatory agent incorporated into the basecoat, the anti-inflammatory agent comprising a rapamycin;
and a topcoat affixed to the basecoat for controlling the elution of the rapamycin from the basecoat into the surrounding tissue, the topcoat comprising a layer of at least 150 micro grams acrylic polymer poly(n-butylmethacrylate) (BMA) coated directly onto the basecoat, wherein the acrylic polymer BMA and the fluoropolymer PVDF/HFP are immiscible and chemically incompatible polymers such that the basecoat and topcoat do not blend and are affixed as separate and distinct layers upon each other to create a physical and chemical barrier to the elution of the rapamycin.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 14/298,154Filed 6 Jun 2014 · division
Priority: 19 Dec 2003
Published: US 2014/0288631 A125 Sep 2014
Granted: 23 Feb 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61F 2/06
Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts: blood vessels
A61F 2/07
Blood vessels: stent-grafts
A61L 31/10
Materials for coatings: macromolecular materials
A61L 31/16
Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface…:…

Family

Application10/742,346Parent of this continuation-in-part · filed 19 Dec 2003
Application11/131,720Parent of this division · filed 18 May 2005
US 8,652,502 B2Parent of this continuation-in-part · filed 18 Feb 2014
US 2014/0288631 A1Pre-grant publication · published 25 Sep 2014
US 8,747,881 B2Parent of this division
Application11/131,720Parent of this continuation-in-part
US 2005/0136090 A1Published application
US 2005/0249775 A1Published application
US 9,265,598 B2This patent

From the US filing history. Foreign family members aren’t listed.